Literature DB >> 2312600

Multiple myeloma: biology and therapy.

B Barlogie1, J Epstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2312600     DOI： 10.1007/bf01612651

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  16 in total

1.  Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806).

Authors:  D E BERGSAGEL; C C SPRAGUE; C AUSTIN; K M GRIFFITH
Journal:  Cancer Chemother Rep       Date:  1962-08

2.  Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes.

Authors:  S Seremetis; G Inghirami; D Ferrero; E W Newcomb; D M Knowles; G P Dotto; R Dalla-Favera
Journal:  Science       Date:  1989-02-03       Impact factor: 47.728

Review 3.  Plasma cell myeloma--new biological insights and advances in therapy.

Authors:  B Barlogie; J Epstein; P Selvanayagam; R Alexanian
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

4.  Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol.

Authors:  F Mandelli; M Tribalto; G Avvisati; M Cantonetti; M T Petrucci; M Boccadoro; A Pileri; F Marmont; L Resegotti; V Lauta
Journal:  Cancer Treat Rev       Date:  1988-01       Impact factor: 12.111

5.  Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.

Authors:  P Selvanayagam; M Blick; F Narni; P van Tuinen; D H Ledbetter; R Alexanian; G F Saunders; B Barlogie
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

6.  High-dose glucocorticoid treatment of resistant myeloma.

Authors:  R Alexanian; B Barlogie; D Dixon
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

7.  Treatment of multiple myeloma with recombinant alpha-interferon.

Authors:  J R Quesada; R Alexanian; M Hawkins; B Barlogie; E Borden; L Itri; J U Gutterman
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

8.  Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma.

Authors:  H Tsuchiya; J Epstein; P Selvanayagam; J R Dedman; G Gallick; R Alexanian; B Barlogie
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

9.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

Authors:  R Bataille; M Jourdan; X G Zhang; B Klein
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

10.  P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.

Authors:  J Epstein; H Q Xiao; B K Oba
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113
View more
  1 in total

1.  Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma.

Authors:  Yousef Faridvand; Ali Eishi Oskuyi; Mohammad-Hassan Khadem-Ansari
Journal:  Redox Rep       Date:  2016-02-26       Impact factor: 4.412
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.